-
Mashup Score: 0
Dr Anthony Quinn, CEO of Aeglea BioTherapeutics, discusses the phase 3 PEACE study, testing pegzilarginase to treat arginase 1 deficiency.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Dr Anthony Quinn, CEO of Aeglea BioTherapeutics, discusses the phase 3 PEACE study, testing pegzilarginase to treat arginase 1 deficiency.
Anthony Quinn, PhD, President and CEO of Aeglea BioTherapeutics, discusses the PEACE study, a phase 3 clinical trial of pegzilarginase for the treatment of arginase 1 #ARG1 deficiency. @aegleabio https://t.co/ngtG1j808D